Exercise intervention lowers aberrant serum WISP-1 levels with insulin resistance in breast cancer survivors: a randomized controlled trial.
Biomarkers
Blood Glucose
/ analysis
Body Composition
Breast Neoplasms
/ blood
CCN Intercellular Signaling Proteins
/ blood
Cancer Survivors
Exercise
Exercise Therapy
Humans
Insulin Resistance
Lipids
/ blood
Middle Aged
Physical Fitness
Proto-Oncogene Proteins
/ blood
Resistance Training
Wnt Signaling Pathway
beta Catenin
/ blood
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 07 2020
02 07 2020
Historique:
received:
07
02
2020
accepted:
11
06
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
18
12
2020
Statut:
epublish
Résumé
Insulin resistance is associated with increased risk for and recurrence of breast cancer. Recently, Wnt1-inducible signaling pathway protein-1 (WISP-1) was reported to impair glucose metabolism and insulin sensitivity. In various cancer tissues, Wnt signaling is upregulated and induces further oncogenic and metastatic activity. However, the effects of exercise on serum levels of WISP-1 and its upstream β-catenin have not been studied in cancer patients. We investigated the effects of exercise training on Wnt signaling and insulin sensitivity in breast cancer survivors (BCS). This single-center trial randomized 46 BCS into either 12-week exercise or control groups (1:1), and included an additional 12 age-matched healthy women. Kinanthropometric parameters, serum Wnt signaling markers, and gluco-lipid profiles were evaluated before and after the intervention. Serum β-catenin and WISP-1 concentrations were significantly higher in BCS than in healthy subjects. There was a positive correlation between β-catenin and WISP-1 levels. Exercise training in BCS significantly reduced body fat and waist circumference and enhanced aerobic and muscular fitness. Exercise decreased β-catenin and WISP-1 levels and improved gluco-lipid profiles. There was a notable correlation between changes in HOMA-IR indexes and serum WISP-1, but not with β-catenin during the exercise intervention. In conclusion, a 12-week community-based exercise intervention resulted in significant reductions in serum β-catenin and WISP-1 levels, accompanied by favorable improvements in body composition, physical fitness, and biochemical parameters in BCS. We also highlight that this is the first report concerning effects of exercise on circulating β-catenin and WISP-1 levels and correlations between WISP-1 and insulin sensitivity, which could be important for determining prognoses for BCS.
Identifiants
pubmed: 32616883
doi: 10.1038/s41598-020-67794-w
pii: 10.1038/s41598-020-67794-w
pmc: PMC7331642
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
CCN Intercellular Signaling Proteins
0
CCN4 protein, human
0
CTNNB1 protein, human
0
Lipids
0
Proto-Oncogene Proteins
0
beta Catenin
0
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10898Références
Juvet, L. K. et al. The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: a meta-analysis. Breast 33, 166–177 (2017).
doi: 10.1016/j.breast.2017.04.003
Fong, D. Y. et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ 344, e70 (2012).
doi: 10.1136/bmj.e70
Binkley, J. M. et al. Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118, 2207–2216 (2012).
doi: 10.1002/cncr.27469
Zeng, Y., Huang, M., Cheng, A. S., Zhou, Y. & So, W. K. Meta-analysis of the effects of exercise intervention on quality of life in breast cancer survivors. Breast Cancer 21, 262–274 (2014).
doi: 10.1007/s12282-014-0521-7
Mijwel, S. et al. High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship. J. Cancer Surviv. 13, 244–256 (2019).
doi: 10.1007/s11764-019-00747-z
McNeely, M. L. et al. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 175, 34–41 (2006).
doi: 10.1503/cmaj.051073
Nusse, R. & Clevers, H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017).
doi: 10.1016/j.cell.2017.05.016
Ghosh, N., Hossain, U., Mandal, A. & Sil, P. C. The Wnt signaling pathway: a potential therapeutic target against cancer. Ann. N. Y. Acad. Sci. 1443, 54–74 (2019).
doi: 10.1111/nyas.14027
Krishnamurthy, N. & Kurzrock, R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat. Rev. 62, 50–60 (2018).
doi: 10.1016/j.ctrv.2017.11.002
Clevers, H. & Nusse, R. Wnt/beta-catenin signaling and disease. Cell 149, 1192–1205 (2012).
doi: 10.1016/j.cell.2012.05.012
Nelson, W. J. & Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 1483–1487 (2004).
doi: 10.1126/science.1094291
MacDonald, B. T., Tamai, K. & He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9–26 (2009).
doi: 10.1016/j.devcel.2009.06.016
Berschneider, B. & Konigshoff, M. WNT1 inducible signaling pathway protein 1 (WISP1): a novel mediator linking development and disease. Int. J. Biochem. Cell Biol. 43, 306–309 (2011).
doi: 10.1016/j.biocel.2010.11.013
Gurbuz, I. & Chiquet-Ehrismann, R. CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): a focus on its role in cancer. Int J Biochem Cell Biol 62, 142–146 (2015).
doi: 10.1016/j.biocel.2015.03.007
Chiang, K. C. et al. WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer. Sci. Rep. 5, 8686 (2015).
doi: 10.1038/srep08686
Tacke, C. et al. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. J Cell Commun Signal, (2017).
Horbelt, T. et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia, (2018).
Murahovschi, V. et al. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes 64, 856–866 (2015).
doi: 10.2337/db14-0444
Cust, A. E. et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res. Treat. 113, 567–576 (2009).
doi: 10.1007/s10549-008-9958-8
Mendonca, F. M. et al. Metabolic syndrome and risk of cancer: which link?. Metabolism 64, 182–189 (2015).
doi: 10.1016/j.metabol.2014.10.008
Carmichael, A. R. Obesity and prognosis of breast cancer. Obes Rev 7, 333–340 (2006).
doi: 10.1111/j.1467-789X.2006.00261.x
Kim, T. H. et al. Effects of exercise training on circulating levels of Dickkpof-1 and secreted frizzled-related protein-1 in breast cancer survivors: A pilot single-blind randomized controlled trial. PLoS ONE 12, e0171771 (2017).
doi: 10.1371/journal.pone.0171771
Irwin, M. L. & American College of Sports Medicine. ACSM's guide to exercise and cancer survivorship xvii, 189 p. (Human Kinetics, 2012).
Haff, G., Triplett, N. T. & National Strength & Conditioning Association (U.S.). Essentials of strength training and conditioning Fourth edition. edn xvi, 735 pages (Human Kinetics, 2016).
Colado, J. C. et al. Concurrent validation of the OMNI-resistance exercise scale of perceived exertion with Thera-band resistance bands. J. Strength Cond. Res. 26, 3018–3024 (2012).
doi: 10.1519/JSC.0b013e318245c0c9
Anderson, L. J., Erceg, D. N. & Schroeder, E. T. Utility of multifrequency bioelectrical impedance compared with dual-energy x-ray absorptiometry for assessment of total and regional body composition varies between men and women. Nutr. Res. 32, 479–485 (2012).
doi: 10.1016/j.nutres.2012.05.009
Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).
doi: 10.1007/BF00280883
Brown, J. C. et al. Randomized trial of a clinic-based weight loss intervention in cancer survivors. J Cancer Surviv. 12, 186–195 (2018).
doi: 10.1007/s11764-017-0657-5
Buchan, J., Janda, M., Box, R., Schmitz, K. & Hayes, S. A randomized trial on the effect of exercise mode on breast cancer-related lymphedema. Med. Sci. Sports Exerc. 48, 1866–1874 (2016).
doi: 10.1249/MSS.0000000000000988
Niida, A. et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 23, 8520–8526 (2004).
doi: 10.1038/sj.onc.1207892
Xu, L., Corcoran, R. B., Welsh, J. W., Pennica, D. & Levine, A. J. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev 14, 585–595 (2000).
pubmed: 10716946
pmcid: 316421
Michaelson, J. S. & Leder, P. beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 20, 5093–5099 (2001).
doi: 10.1038/sj.onc.1204586
Khramtsov, A. I. et al. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176, 2911–2920 (2010).
doi: 10.2353/ajpath.2010.091125
Xie, D., Nakachi, K., Wang, H., Elashoff, R. & Koeffler, H. P. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61, 8917–8923 (2001).
pubmed: 11751417
Jun, J. I. & Lau, L. F. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10, 945–963 (2011).
doi: 10.1038/nrd3599
Ono, M. et al. WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone. PLoS ONE 8, e71709 (2013).
doi: 10.1371/journal.pone.0071709
Sieri, S. et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 130, 921–929 (2012).
doi: 10.1002/ijc.26071
Esposito, K., Chiodini, P., Colao, A., Lenzi, A. & Giugliano, D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35, 2402–2411 (2012).
doi: 10.2337/dc12-0336
Berrino, F. et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res. Treat. 147, 159–165 (2014).
doi: 10.1007/s10549-014-3076-6
Sparks, L. M. Exercise training response heterogeneity: physiological and molecular insights. Diabetologia 60, 2329–2336 (2017).
doi: 10.1007/s00125-017-4461-6
Irwin, M. L. et al. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J. Clin. Oncol. 26, 3958–3964 (2008).
doi: 10.1200/JCO.2007.15.9822
Jones, L. W. et al. Exercise and prognosis on the basis of clinicopathologic and molecular features in early-stage breast cancer: the LACE and pathways studies. Cancer Res. 76, 5415–5422 (2016).
doi: 10.1158/0008-5472.CAN-15-3307
Betof, A. S., Dewhirst, M. W. & Jones, L. W. Effects and potential mechanisms of exercise training on cancer progression: a translational perspective. Brain Behav. Immun. 30(Suppl), S75-87 (2013).
doi: 10.1016/j.bbi.2012.05.001